Solensia
سولينسيا
Solensia (frunevetmab) is the first feline-specific monoclonal antibody therapy targeting Nerve Growth Factor (NGF) approved for the alleviation of pain associated with osteoarthritis in cats, administered once monthly by a veterinarian.
Dosage Form
Injection
Product Type
Biological
Manufacturer
Package
Cartons of 2 or 6 single-use vials, each containing 7 mg/mL frunevetmab in 1 mL solution
Dosages
| Species | Dosage | Route | Duration |
|---|---|---|---|
| Cat | Minimum 1.0 mg/kg body weight (cats 2.5–7.0 kg: 1 vial / 7 mg; cats 7.1–14.0 kg: 2 vials / 14 mg) | Subcutaneous (SC) | Once monthly |
Withdrawal Periods
No withdrawal information available.
Indications
-
Control and alleviation of pain associated with osteoarthritis in cats.
Contraindications
-
Do not use in cats with known hypersensitivity to frunevetmab.
-
Do not use in breeding, pregnant, or lactating cats.
-
Do not use in cats less than 2.5 kg (5.5 lbs) body weight or under 7 months of age.
Precautions
-
Safety has not been evaluated in cats with advanced renal disease (IRIS stage 3 or 4).
-
May induce transient local skin reactions (focal alopecia, dermatitis, pruritus around head and neck).
-
Frunevetmab is metabolized via standard protein breakdown processes.
Side Effects
-
Skin reactions (pruritus, dermatitis, alopecia), vomiting, diarrhea, lethargy, anorexia, and injection site pain.
Images
Documents
-
Download
Solensia Prescribing Information
Leaflet
Active Ingredients
-
Frunevetmab
7 mg/mL
Diseases
No diseases linked.
Related Products
No data available
Information has not been added yet.
Related Products By Active Ingredient
No data available
Information has not been added yet.
Companies
-
Zoetis
Manufacturer
Alternatives
No alternatives available.